Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated results: Phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy
    Meeting Abstract

    Geyer, M. B.; Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • RNA binding protein SYNCRIP regulates the leukemia stem cell program
    Meeting Abstract

    Vu, L. P.; Prieto, C.; Amin, E.; Minuesa, G.; Chhangawala, S.; Vidal, M. J.; Krivtsov, A. V.; Chou, T.; Barlowe, T.; Taggart, J.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • JAK2V617F promotes atherosclerosis
    Meeting Abstract

    Wang, W.; Wang, Y.; Woods, B.; Abramowicz, S.; Welch, C.; Levine, R. L.; Tall, A.; Wang, N.
    Blood (2016)

    Fulltext@MSK | Save
  • Activation of JAK/STAT signaling in megakaryocytes is necessary and sufficient for myeloproliferation in vivo
    Meeting Abstract

    Wen, Q. J.; Woods, B.; Yang, Q.; Sophia, C.; Lillu, G.; Rapaport, F.; Levine, R. L.; Crispino, J.
    Blood (2016)

    Fulltext@MSK | Save
  • Enasidenib (AG-221), a potent oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS)
    Meeting Abstract

    Stein, E. M.; Fathi, A. T.; DiNardo, C. D.; Pollyea, D. A.; Swords, R. T.; Roboz, G. J.; Collins, R.; Sekeres, M. A.; Stone, R. M.; Attar, E. C.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) harbors frequent splicesosome mutations that cause aberrant RNA splicing affecting genes critical in pDC differentiation and function
    Meeting Abstract

    Togami, K.; Madan, V.; Li, J.; Villani, A. C.; Sarkizova, S.; Ghandi, M.; Buczkowski, K.; Li, Y.; Biichle, S.; Angelot-Delettre, F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Changes of the mutational landscape in relapsed acute myeloid leukemia
    Meeting Abstract

    Rapaport, F.; de Massy, M. R.; al Hinai, A.; Sanders, M. A.; Hricik, T.; Sheridan, C.; Lee, T. C.; Neelamraju, Y.; Patel, J.; Chung, S. S.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Durable overall survival benefit in patients >= 60 years with relapsed or refractory AML treated with vosaroxin/cytarabine vs placebo/cytarabine: Updated results from the valor trial
    Meeting Abstract

    Ravandi, F.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M.; Vey, N.; Strickland, S. A.; Schiller, G. J.; Jabbour, E. J.; Erba, H. P.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Synergistic therapeutic efficacy of combined JAK1/2, pan-PIM, and CDK4/6 inhibition in myeloproliferative neoplasms
    Meeting Abstract

    Rampal, R. K.; Maria, P. O.; Amritha Varshini, H. S.; Levine, R. L.; Cao, A.
    Blood (2016)

    Fulltext@MSK | Save
  • Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma
    Meeting Abstract

    Mondello, P.; Derenzini, E.; Asgari, Z.; Philip, J.; Brea, E. J.; Seshan, V. E.; Hendrickson, R.; de Stanchina, E.; Scheinberg, D. A.; Younes, A.
    Blood (2016)

    Fulltext@MSK | Save